Moreover, depletion of USP7 induces ROS accumulation and overcomes the resistance to osimertinib, which is a first-line therapy in advanced NSCLC patients harboring EGFR-activating or T790 M resistance mutations [44]. Here, USP7 is linked to non-small cell lung carcinoma.